# Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

> **NCT01127841** · PHASE2 · UNKNOWN · sponsor: **Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas** · enrollment: 60 (estimated)

## Conditions studied

- Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

## Interventions

- **DRUG:** Rituximab and Bendamustine

## Key facts

- **NCT ID:** NCT01127841
- **Lead sponsor:** Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2013-12
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127841, "Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01127841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*